Clinical Perspectives on Dual Checkpoint Blockade for mNSCLC Dual checkpoint blockade is becoming a more common approach for patients with mNSCLC and no targetable driver mutation, and a new regimen was recently approved. Join us to hear from a thoracic oncologist, Christine Bestvina, MD, about how these regimens are changing patients’ perspectives about their likely […]

The post Clinical Perspectives on Dual Checkpoint Blockade for mNSCLC first appeared on Medical Learning Institute Inc.